We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

3 hedge funds and large institutions have $56.7K invested in NeuroSense Therapeutics Warrant in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more capital invested

Capital invested by funds: $24.6K → $56.7K (+$32.1K)

50% more funds holding

Funds holding: 2 → 3 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CS
Clear Street
New York
-$107
2
UBS Group
UBS Group
Switzerland
-$42

NRSNW Hedge Fund Activity: Q4 2025 in Review

3 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2025, worth a combined $56.7K — up 131% from $24.6K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest seller was Clear Street, cutting an estimated $107.

  • 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2025, up from 2 in Q3 2025.
  • Funds reported $56.7K of NeuroSense Therapeutics Warrant stock for Q4 2025, up 131% quarter-over-quarter.
  • 1 fund opened new NeuroSense Therapeutics Warrant positions in Q4 2025 and 0 closed out, a net change of +1 holder.
  • The largest NeuroSense Therapeutics Warrant seller in Q4 2025 was Clear Street, an estimated $107 sold.

Based on aggregated 13F filings for Q4 2025.